The purpose of our study was (i) to evaluate the impact of alltrans retinoic acid (ATRA) given as adjunct to chemotherapy and (ii) to compare second consolidation vs maintenance therapy in elderly patients with acute myeloid leukemia (AML). A total of 242 patients aged X61 years (median, 66.6 years) with AML were randomly assigned to ATRA beginning on day þ 3 after the initiation of chemotherapy (ATRA-arm, n ¼ 122) or no ATRA (standard-arm, n ¼ 120) in combination with induction and first consolidation therapy. A total of 61 patients in complete remission (CR) were randomly assigned to second intense consolidation (n ¼ 31) or 1-year oral maintenance therapy (n ¼ 30). After induction therapy the intention-to-treat analysis revealed a significant difference in CR rates between the ATRA-and the standard-arm (52 vs 39%; P ¼ 0.05). Eventfree (EFS) and overall survival (OS) were significantly better in the ATRA-compared to the standard-arm (P ¼ 0.03 and 0.01, respectively). OS after second randomization was significantly better for patients assigned to intensive consolidation therapy (Po0.001). The multivariate model for survival revealed lactate dehydrogenase, cytogenetic risk group, age, and first and second randomization as prognostic variables. In conclusion, the addition of ATRA to induction and consolidation therapy may improve CR rate, EFS and OS in elderly patients with AML.
Introduction
The intensification of induction and postremission therapy has improved the outcome of younger patients with acute myeloid leukemia (AML). However, in patients over the age of 60 years treatment results have been consistently inferior with complete remission (CR) rates of 40-60% and only 10-20% of patients surviving 4 years. [1] [2] [3] [4] [5] [6] [7] The differences in response and outcome are multifactorial. There is an increase of unfavorable biological characteristics of the disease in elderly patients, such as higher proportion of unfavorable karyotypes, 8, 9 higher frequency of multidrug resistance mediator P-glycoprotein expression, 10 and higher frequency of antecedent hematologic disorders or of previous treatment for another malignancy.
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High levels of the antiapoptotic protein bcl-2 in AML blasts were reported to be associated with an unfavorable outcome after chemotherapy. [12] [13] [14] [15] Thus, bcl-2 represents another potential target in AML treatment. In vitro data suggested that the addition of retinoids, for example, all-trans retinoic acid (ATRA), to cultures of AML blasts in combination with cytarabine or idarubicin increased killing of clonogenic cells by downregulation of bcl-2. [16] [17] [18] [19] [20] [21] The sequence may be important when combining ATRA with cytotoxic drugs: synergistic effects were only seen when ATRA was administered after cytotoxic drug exposure, whereas preincubation with ATRA could even inhibit cytotoxic drug-induced cell killing. 16, 17, 21, 22 These in vitro data were supported by results from one clinical trial. In a small phase II study, Venditti et al 23 showed that the combination of low-dose cytarabine given subcutaneously in combination with ATRA resulted in a remarkably high CR rate in a poor prognosis AML patient population.
In 1998, we initiated a randomized trial to assess the effect of ATRA given in combination with age-adapted induction 24 and consolidation chemotherapy on CR rate, event-free survival (EFS) and overall survival (OS) in elderly patients with AML. Based on the in vitro data, ATRA was applied after exposure to the cytotoxic drugs.
Methods

Patients
Patients 61 years or older with de novo AML or refractory anemia with excess of blasts in transformation (RAEB-t) defined by the French-American-British (FAB) classification system, 25 secondary AML (s-AML) with a preceding history of myelodysplasia at least 3 months before the diagnosis of AML, or therapyrelated AML following treatment of primary malignant disease (t-AML) were eligible for entry into the trial. Patients with acute promyelocytic leukemia (APL), patients with concomitant liver, renal or cardiac disease and patients with a performance status WHO 42 were not included. Chromosome banding analysis using standard methods was performed centrally for all patients in the Laboratory for Cytogenetic and Molecular Diagnostics of the AML Study Group Ulm (AMLSG ULM). The description of the karyotype followed the recommendations of the International System for Human Cytogenetic Nomenclature. 26 Written informed consent was obtained at study entry. The study was approved by the local Ethics Review Committees.
First and second randomization
Patients were randomized via a telephone call to the AMLSG ULM study office to either induction and consolidation chemotherapy without ATRA (standard-arm) or to the same chemotherapy plus ATRA (ATRA-arm 
Criteria for response and definition of relapse
Response assessment during induction therapy was performed at two time points and was defined differently. The first time point was between days 28 and 35 after first induction therapy. AML patients either in CR 29 or in PR and RAEB-t with a X50% reduction of bone marrow blasts compared to the pretreatment status were considered as responders to the first induction cycle and were eligible for the second cycle. The second time point of response assessment was after two cycles of induction therapy. Response was defined by achievement of CR. 29 Causes of therapeutic failure were RD or death during induction therapy (early death: ED) or induced bone marrow hypoplasia (hypoplastic death: HD). Relapse was defined as a marrow with 45% blasts unrelated to recovery of blood counts from preceding course of chemotherapy or new extramedullary leukemia in patients with previously documented CR.
Statistical analysis
The primary end point for first randomization was achievement of CR after two cycles of induction therapy; secondary end points were EFS, OS, cumulative incidence of relapse (CIR) and toxicity related to ATRA. The study sample size of n ¼ 242 patients for the first randomization was calculated to detect a 0.2 difference in CR rate between the null hypothesis that both group proportions are 0.5 and the alternative hypothesis that the proportion in the ATRA-arm is 0.7 based on a one-sided w 2 test with continuity correction having a power of 80% and type I error of 5%. The interim analysis in 2001 after randomization of 242 patients between the standard-arm and the ATRA-arm revealed on a per-protocol basis no difference in CR rate between the two arms. According to the protocol, it was decided that all further patients received the standard-arm either until the required sample size of 100 patients for second randomization was achieved or rules of stopping recommended termination of second randomization. The presented data include the final analysis of first randomization and the interim analysis of the second randomization. Based on these results, second randomization was stopped in April 2003. Focus of this report is the analysis of the 242 patients randomized for the first part of the study.
For the assessment of first randomization, EFS and OS were measured from study entry. For EFS, events were defined by ED/HD during induction therapy (failure), no CR after two cycles of induction therapy (failure), relapse (failure), death in CR (failure), allogeneic transplantation in CR (censored) and alive in CR at last follow-up (censored). OS times of patients being alive at last follow-up or at the date of allogeneic transplantation were censored. The analyses of CIR and the cumulative incidence of death in CR (CID) included only patients achieving CR with time calculated from date of CR until event (relapse or death in CR). CIR, CID, their standard errors (s.e.) and differences between groups were estimated using the method of Gray. 30 The median duration of follow-up was calculated according to the method of Korn. 31 Survival distributions were compared using the log-rank test. For multivariate analysis, an extended Cox model was used including the second randomization as time-dependent covariate. 32 The statistical analyses were performed with the statistical software packages SAS (SAS Institute Inc., Cary, NC, USA) and R, version 1.6.2 33 together with the Design software library. 34 
Results
Accrual of patients
Between February 1998 and September 2001, 253 patients were registered for the study. Of these patients, 10 had concomitant disease (heart failure, n ¼ 5; other cancer, n ¼ 3; hepatic insufficiency, n ¼ 1; renal failure, n ¼ 1) and one patient was not randomized due to thrombocytopenia unresponsive to transfusions. Thus, 242 patients were randomized, 120 to the standard-arm and 122 to the ATRA-arm. Table 1 shows the distribution of clinical parameters by up-front treatment assignment. The trial is summarized in the flow diagram in Figure 1 .
Induction and first consolidation therapy
Response: Response to the first cycle of induction is summarized in Toxicity: In the ATRA-arm, five and four patients intermittently discontinued ATRA during first and second induction therapy, respectively; there was no case of ATRA discontinuation during first consolidation therapy. The causes of ATRA discontinuation were fever, weight gain, exanthema and edema, appearing in all cases at the same time with the onset of infection. None of the patients receiving ATRA developed pancreatitis, hepatitis, cheilitis or an ATRA syndrome. There was no difference in toxicity and supportive care for induction and first consolidation therapy between the two treatment arms. The results for the first induction cycle are summarized in Table 3 .
Allogeneic transplantation and second randomization
Of the 242 randomized patients, 11 received dose-reduced conditioning followed by allogeneic transplantation from an HLA-identical family donor. Seven patients were transplanted in first CR and four patients were transplanted with refractory AML. Two of the latter patients achieved a CR after transplantation. Two patients died from treatment-related toxicity (cardiac failure, aspergillus pneumonia) and two patients relapsed 10 and 11 months after transplantation. Five patients are in continuous CR ranging from 18 to 101 months from the time of transplantation.
A total of 61 patients in CR after first consolidation were randomized between a second intensive consolidation therapy with IEiv (n ¼ 31) and a 1-year maintenance therapy with IEpo (n ¼ 30). Baseline characteristics of the 61 randomized patients were well balanced between the two arms.
Analysis of survival and cumulative incidence of relapse
The estimated median follow-up time for OS was 34 months. Out of the 242 patients, 204 have died. The median OS time for the entire group was 10 months (95% CI 7.4-11.9 months) and OS after 34 months was 14% (95% CI 10-20%). For the 115 patients who entered CR, CIR after 34 months was 80% (s.e. 4.1%). The total number of administered intensive chemotherapy cycles within or outside the protocol was a median of 3 cycles (1-8) with no difference between the two treatment arms (ATRA-arm, standard-arm). The comparison of EFS distributions according to first randomization on the intention-to-treat principle showed a statistically significant benefit (P ¼ 0.03) for the ATRA-arm compared to the standardarm. This led to a statistically significant better OS (P ¼ 0.01) with estimated median survival times of 11.3 and 7.0 months in the ATRA-and the standard-arm, respectively (Figure 2 ). There were no statistically significant differences in CIR (P ¼ 0.35) or CID (P ¼ 0.27) between the two treatment arms. End points for second randomization were survival and CIR beginning from date of randomization. On the intention-to-treat principle, there was a statistically significant reduced CIR for patients randomized to a second intensive consolidation therapy compared to maintenance therapy (P ¼ 0.002) with a CIR at 12 months after randomization of 39% (s.e. 9%) for the IEiv-arm and 80% (s.e. 8%) for the IEpo-arm translating into a significantly (Po0.001) better survival for patients randomized to a second intensive consolidation therapy.
Multivariate analysis for survival included all patients (n ¼ 242) examined, Log(WBC), Log(LDH), age, bone marrow blasts, platelet count, cytogenetic group according to the MRC classification, 35 type of AML (de novo vs s-AML/t-AML or RAEB-t), first randomization and second randomization as time-dependent covariates. This analysis revealed LDH (P ¼ 0.005), cytogenetic group (high-risk vs others) (P ¼ 0.005), age (P ¼ 0.007), first randomization (P ¼ 0.01) and second randomization (Po0.001) as statistically significant prognostic variables (Table 4) . According to MRC criteria. 35 
Discussion
The principle conclusion of this study is that the addition of ATRA to standard induction and consolidation therapy may improve response rate, EFS and OS in elderly patients with AML. When considering CR and PR after the first induction therapy, there was a significantly higher response rate in the ATRA-arm, indicating a higher initial bone marrow blast clearance (Table 2) . This higher initial response may have led to the significantly higher CR rate in the ATRA-arm following two cycles of induction therapies. This difference could be demonstrated in an intention-to-treat analysis -also taking into account further intense treatment outside the protocol -but not in a per-protocol analysis. Therefore, the addition of ATRA to first induction therapy seems to be crucial for this beneficial effect since the results of the ATRA containing salvage regimen (A-HAE) were disappointing. The rationale for the addition of ATRA was to increase the sensitivity of leukemic cells for the effect of the Up front ont r random andomized ized pat patient ients s (n=242) =242)
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Figure 1
Summary of the AML HD98B treatment trial. Table 3 Toxicity and supportive care requirements during induction course 1 by up-front treatment assignment
Hematological toxicity Median duration of neutropenia o0.5 Â 10 9 /l (days) 19 19
Median duration of thrombopenia o20 Â 10 9 /l (days) 16 15 cytotoxic drugs. In vitro, such a sensitizing effect had been shown for the antileukemic agents cytarabine and idarubicin, 16, 19, 21, 22 which were both administered in induction therapy of the current study. The initial in vitro data suggested that ATRA may exert its effect by downregulation or by posttranslational modification of the antiapoptotic protein bcl-2. 21, 36 More recently, further proteins, for example, survivin as a member of the inhibitors of apoptosis family, have been described as potential targets of ATRA. 37 There have been three other trials evaluating ATRA in non-APL AML (Burnett et al, Blood 2002; 100: 582; abstract). 38, 39 In the two randomized trials, there was no significant effect on survival; however, there are relevant differences among the trials with respect to patient selection and scheduling of ATRA along with the cytotoxic drugs. Estey et al studied a high-risk population, including patients over the age of 70 years (32%), with s-AML (66%) and t-AML (26%). Interestingly, in the study of Estey et al, univariate analysis revealed a statistically significant better OS in the two arms containing ATRA, whereas multivariate analysis suggested no effect of ATRA. This phase II trial with four treatment arms with 53 patients in each arm had a significantly lower statistical power to detect differences in survival compared to our phase III study. Multivariate analysis in our phase III study indicated a statistically significant benefit for ATRA on survival, which was independent of the effect of second randomization. In the MRC-12 trial, ATRA was evaluated in younger AML patients (up to the age of 55 years); the analysis may be complicated by the multifactorial design of the entire trial evaluating in parallel the impact of autologous transplantation and the impact of a fifth cycle of treatment. A second and potentially more important issue relates to the scheduling of ATRA: in the study reported by Estey et al, ATRA was commenced at day À2, that is, prior to the start of induction chemotherapy, and in the MRC-12 trial as well as the study reported by Bolanos-Meade et al 39 ATRA was started simultaneously with chemotherapy. In contrast, in our study, ATRA was administered at day þ 3, that is, at a time point where a significant proportion of the cytotoxic drugs had already been administered to the patient. This schedule was based on in vitro data showing that the sensitizing effect of ATRA was only seen when ATRA was given after the cytotoxic drugs. 16, 19, 21, 22 Thus, the initial higher blast clearance as seen in our study using such a time-sequential schedule may parallel the in vitro observations. OS for the up-front randomized treatment arms; the difference between the curves was statistically significant (P ¼ 0.01). 
